candesartan has been researched along with Atherogenesis in 16 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 7.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 7.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| "AT1 antagonists effectively prevent atherosclerosis since AT1 upregulation and angiotensin II-induced proinflammatory actions are critical to atherogenesis." | 3.81 | MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. ( da Silva, CHTP; de Oliveira, AM; do Prado, AF; Gerlach, RF; Gomes, MS; Pernomian, L, 2015) |
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 3.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 3.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| " Candesartan significantly reduced aortic atherosclerosis, prevented the upregulation of the uraemia-induced genes and led to changes predicting greater stability of the plaques, without influencing blood pressure or serum lipids." | 3.77 | Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. ( Bernardi, S; Candido, R; Carretta, R; Fabris, B; Toffoli, B, 2011) |
| "Telmisartan is a unique angiotensin II (Ang II) receptor blocker (ARB) with selective peroxisome proliferator-activated receptor-gamma (PPAR gamma)." | 1.35 | Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K, 2008) |
| "Atherosclerotic renal artery stenosis is a problem with no consensus on diagnosis or therapy." | 1.33 | Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. ( Cohen, DJ; Cooper, CJ; D'Agostino, R; Dworkin, L; Henrich, W; Jaff, M; Jamerson, K; Kuntz, R; Matsumoto, A; Murphy, TP; Reid, D; Rosenfield, K; Rundback, J; Steffes, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hadi, NR | 1 |
| Yousif, NG | 1 |
| Abdulzahra, MS | 1 |
| Mohammad, BI | 1 |
| Al-Amran, FG | 1 |
| Majeed, ML | 1 |
| Yousif, MG | 1 |
| Pernomian, L | 2 |
| do Prado, AF | 1 |
| Gomes, MS | 1 |
| da Silva, CHTP | 1 |
| Gerlach, RF | 1 |
| de Oliveira, AM | 1 |
| Chow, BS | 1 |
| Koulis, C | 1 |
| Krishnaswamy, P | 1 |
| Steckelings, UM | 1 |
| Unger, T | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Hoshide, S | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Kanome, T | 1 |
| Watanabe, T | 1 |
| Nishio, K | 1 |
| Takahashi, K | 1 |
| Hongo, S | 1 |
| Miyazaki, A | 1 |
| Bernardi, S | 1 |
| Candido, R | 1 |
| Toffoli, B | 1 |
| Carretta, R | 1 |
| Fabris, B | 1 |
| Suzuki, T | 1 |
| Nozawa, T | 1 |
| Fujii, N | 1 |
| Sobajima, M | 1 |
| Ohori, T | 1 |
| Shida, T | 1 |
| Matsuki, A | 1 |
| Kameyama, T | 1 |
| Inoue, H | 1 |
| Marson, BP | 1 |
| Poli de Figueiredo, CE | 1 |
| Tanus-Santos, JE | 1 |
| Hayashi, K | 1 |
| Sasamura, H | 1 |
| Azegami, T | 1 |
| Itoh, H | 1 |
| Wassmann, K | 1 |
| Ghiassi, A | 1 |
| Wassmann, S | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| Chen, J | 1 |
| Li, D | 1 |
| Schaefer, R | 1 |
| Mehta, JL | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Matsumoto, A | 1 |
| Steffes, M | 1 |
| Cohen, DJ | 1 |
| Jaff, M | 1 |
| Kuntz, R | 1 |
| Jamerson, K | 1 |
| Reid, D | 1 |
| Rosenfield, K | 1 |
| Rundback, J | 1 |
| D'Agostino, R | 1 |
| Henrich, W | 1 |
| Dworkin, L | 1 |
| Furuya, R | 1 |
| Odamaki, M | 1 |
| Kumagai, H | 1 |
| Hishida, A | 1 |
| Doran, DE | 1 |
| Weiss, D | 1 |
| Zhang, Y | 1 |
| Griendling, KK | 1 |
| Taylor, WR | 1 |
| Ikejima, H | 1 |
| Imanishi, T | 1 |
| Tsujioka, H | 1 |
| Kuroi, A | 1 |
| Kobayashi, K | 1 |
| Shiomi, M | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
1 review available for candesartan and Atherogenesis
| Article | Year |
|---|---|
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Doxycycline; Humans; K | 2012 |
1 trial available for candesartan and Atherogenesis
| Article | Year |
|---|---|
AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; | 2006 |
14 other studies available for candesartan and Atherogenesis
| Article | Year |
|---|---|
Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2013 |
MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Ao | 2015 |
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles | 2016 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Ischemic nephropathy in an elderly patient.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Female; Humans; | 2008 |
Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; At | 2008 |
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzimi | 2011 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastat | 2011 |
Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan.
Topics: Acetyl-CoA C-Acetyltransferase; Angiotensin Receptor Antagonists; Animals; Apolipoproteins E; Athero | 2012 |
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2006 |
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biph | 2006 |
Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Bipheny | 2006 |
Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Aorta; Atherosclerosis; Benzimidazoles; Biphe | 2007 |
Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta, Abdominal; Aorta, Thoracic; Ather | 2008 |